(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are GameStop, Fluent, and Erytech Pharma S.A..

The three biggest losers today are Diversified Healthcare Trust , Corbus Pharmaceuticals Holdings, and Entera Bio Ltd..

Winners today

1. GameStop (GME) – 41.1%

GameStop Corp., a specialty retailer, provides games and entertainment products through its e-commerce properties and various stores in the United States, Canada, Australia, and Europe. The company sells new and pre-owned gaming platforms; accessories, such as controllers, gaming headsets, virtual reality products, and memory cards; new and pre-owned gaming software; and in-game digital currency, digital downloadable content, and full-game downloads. It also sells collectibles comprising licensed merchandise primarily related to the gaming, television, and movie industries, as well as pop culture themes. It operates ecommerce sites under the GameStop, EB Games, and Micromania brands; and 50 pop culture themed stores that sell collectibles, apparel, gadgets, electronics, toys, and other retail products under the Zing Pop Culture brand, as well as offers Game Informer, a print and digital video game publication featuring reviews of new releases, previews of the big titles on the horizon, and coverage of the latest developments in the gaming industry. The company was formerly known as GSC Holdings Corp. GameStop Corp. was founded in 1996 and is headquartered in Grapevine, Texas.

NYSE ended the session with GameStop rising 41.1% to $24.91 on Wednesday while NYSE fell 0.35% to $14,933.06.

Gamestop (gme) Q4 earnings and revenues surpass estimatesFollowing the better-than-expected results, GameStop shares rallied 48.4% after the trading session on Mar 21.

Meme stocks AMC and bed, bath & beyond boosted by gamestop rallyMeanwhile, GameStop shares ran up 42.8% premarket, putting them on track to open at a 3 1/2-month high.

: amc, bed bath & beyond stocks get a big lift as ‘meme’ peer gamestop shares soarMeanwhile, GameStop shares ran up 42.8% premarket, putting them on track to open at a 3 1/2-month high.

Earnings Per Share

As for profitability, GameStop has a trailing twelve months EPS of $-1.79.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -33.92%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GameStop’s stock is considered to be oversold (<=20).

Previous days news about GameStop

• : gamestop stock extends sharp bounce off 2-year low ahead of earnings report. According to MarketWatch on Tuesday, 21 March, "Shares of GameStop Corp. ran up 6.0% in afternoon trading Tuesday, and have hiked up 12.0% in the four days since they closed at a two-year low, ahead of the consumer electronics retailer’s earnings report, which is due out after the close. "
• Gamestop (gme) beats Q4 earnings and revenue estimates. According to Zacks on Tuesday, 21 March, "While GameStop has underperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?"

More news about GameStop.

2. Fluent (FLNT) – 17.01%

Fluent, Inc. provides data-driven digital marketing services primarily in the United States. The company also offers customer acquisition services by operating digital marketing campaigns, through which the company connects its advertiser clients with consumers. It delivers data and performance-based marketing executions to approximately 500 consumer brands, direct marketers, and agencies across a range of industries, including financial products and services, media and entertainment, health and wellness, retail and consumer, and staffing and recruitment. Fluent, Inc. is headquartered in New York, New York.

NASDAQ ended the session with Fluent jumping 17.01% to $0.83 on Wednesday while NASDAQ jumped 0.07% to $11,868.80.

Earnings Per Share

As for profitability, Fluent has a trailing twelve months EPS of $-1.43.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -80.25%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Fluent’s EBITDA is 32.66.

Moving Average

Fluent’s value is way under its 50-day moving average of $1.39 and way under its 200-day moving average of $1.33.

More news about Fluent.

3. Erytech Pharma S.A. (ERYP) – 15.6%

ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine-dependent cancers. It has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria; and Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. The company was incorporated in 2004 and is headquartered in Lyon, France.

NASDAQ ended the session with Erytech Pharma S.A. rising 15.6% to $0.81 on Wednesday while NASDAQ rose 0.07% to $11,868.80.

Earnings Per Share

As for profitability, Erytech Pharma S.A. has a trailing twelve months EPS of $-1.

Yearly Top and Bottom Value

Erytech Pharma S.A.’s stock is valued at $0.81 at 17:32 EST, way below its 52-week high of $2.18 and way higher than its 52-week low of $0.30.

Revenue Growth

Year-on-year quarterly revenue growth declined by 58.5%, now sitting on 2.2M for the twelve trailing months.

More news about Erytech Pharma S.A..

4. Aspen Group (ASPU) – 13.69%

Aspen Group, Inc., an education technology company, provides online higher education services in the United States. The company offers baccalaureate, master's, and doctoral degree programs in nursing and health sciences, business and technology, arts and sciences, and education fields through Aspen University and United States University. As of April 30, 2022, it had 13,334 degree-seeking students enrolled. Aspen Group, Inc. was founded in 1987 and is based in New York, New York.

NASDAQ ended the session with Aspen Group jumping 13.69% to $0.12 on Wednesday while NASDAQ rose 0.07% to $11,868.80.

Earnings Per Share

As for profitability, Aspen Group has a trailing twelve months EPS of $-0.46.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -28.28%.

Yearly Top and Bottom Value

Aspen Group’s stock is valued at $0.12 at 17:32 EST, way below its 52-week high of $1.91 and way higher than its 52-week low of $0.10.

Moving Average

Aspen Group’s worth is way under its 50-day moving average of $0.24 and way under its 200-day moving average of $0.56.

Sales Growth

Aspen Group’s sales growth is negative 23.5% for the ongoing quarter and negative 25.9% for the next.

More news about Aspen Group.

5. American Public Education (APEI) – 13.4%

American Public Education, Inc., together with its subsidiaries, provides online and campus-based postsecondary education. The company operates through three segments: American Public University System, Rasmussen University, and Hondros College of Nursing. It offers 130 degree programs and 111 certificate programs in various fields of study, including business administration, health science, technology, criminal justice, education, and liberal arts, as well as national security, military studies, intelligence, and homeland security. The company also provides nursing-and health sciences-focused postsecondary education, diploma in practical nursing, an associate degree in nursing, and an associate degree in medical laboratory technology. American Public Education, Inc. was incorporated in 1991 and is headquartered in Charles Town, West Virginia.

NASDAQ ended the session with American Public Education jumping 13.4% to $4.57 on Wednesday while NASDAQ jumped 0.07% to $11,868.80.

Earnings Per Share

As for profitability, American Public Education has a trailing twelve months EPS of $-6.04.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -30.05%.

More news about American Public Education.

6. Calyxt (CLXT) – 12.28%

Calyxt, Inc., a technology company, focuses on delivering plant-based solutions in the United States. It engages in the development of improved digestibility alfalfa; high fiber wheat; high oleic low linolenic soybeans; winter oats; hemp; fat soybeans; and cold storable potatoes. As of March 4, 2021, the company had nine projects at Phase I stage or later in development across alfalfa, hemp, oats, soybeans, and wheat. Calyxt, Inc. has a research collaboration with NRGene, which includes the adoption of NRGene's cloud-based genomics platform to support various research projects; and a commercialization agreement with S&W Seed Company for the exclusive license of an improved quality alfalfa seed in the United States and various geographies outside the United States. It also has a strategic alliance with J.R. Simplot Company to drive new breeding techniques for strawberries, including gene editing. The company was formerly known as Cellectis Plant Sciences, Inc. and changed its name to Calyxt, Inc. in May 2015. Calyxt, Inc. was incorporated in 2010 and is headquartered in Roseville, Minnesota. Calyxt, Inc. is a subsidiary of Cellectis S.A.

NASDAQ ended the session with Calyxt jumping 12.28% to $0.36 on Wednesday, following the last session’s upward trend. NASDAQ jumped 0.07% to $11,868.80, after two sequential sessions in a row of gains, on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, Calyxt has a trailing twelve months EPS of $-0.35.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -158.12%.

Yearly Top and Bottom Value

Calyxt’s stock is valued at $0.36 at 17:32 EST, way under its 52-week high of $1.33 and way higher than its 52-week low of $0.13.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Calyxt’s stock is considered to be oversold (<=20).

Moving Average

Calyxt’s worth is above its 50-day moving average of $0.34 and way above its 200-day moving average of $0.24.

More news about Calyxt.

7. Creative Realities (CREXW) – 11.11%

NASDAQ ended the session with Creative Realities jumping 11.11% to $0.00 on Wednesday, after five successive sessions in a row of losses. NASDAQ jumped 0.07% to $11,868.80, after two successive sessions in a row of gains, on what was a somewhat up trend exchanging session today.

Yearly Top and Bottom Value

Creative Realities’s stock is valued at $0.00 at 17:32 EST, under its 52-week low of $0.00.

More news about Creative Realities.

8. Niu Technologies (NIU) – 8.58%

Niu Technologies designs, manufactures, and sells smart electric scooters in the People's Republic of China. The company offers NQi, MQi, UQi, and Gova series electric scooters and motorcycles; KQi series electric kick-scooters; NIU Aero and BQi series e-bikes; RQi and TQi series high-performance motorcycles; and YQi series hybrid motorcycles. It also provides accessories and spare parts under the NIU brand name comprising scooter accessories, such as raincoats, gloves, knee pads, storage baskets and tail boxes, smart phone holders, backrests, and locks; lifestyle accessories, which includes T-shirts, coats, sweaters and hoodies, jeans, hats, bags, jewelry, notebook, badges, key chain, and mugs; and performance upgrade components that comprises of upgraded wheels, shock absorbers, brake calipers, and carbon fiber body panels. In addition, the company, through its NIU app, offers online repair request, DIY repairs, service station locator, theft reporting, and smart services, as well as NIU cover, which provides insurance services; NIU Care that offers maintenance and reserve services in offline service stations; and NIU Wash, which provides free wash coupon on a monthly basis. Niu Technologies sells and services its products through city partners and franchised stores, distributors, and third-party e-commerce platforms and the company's online store. As of December 31, 2021, it operated through 338 city partners and 3,108 franchised stores in approximately 239 cities in the People's Republic of China; and 42 distributors in 50 countries internationally. Niu Technologies was incorporated in 2014 and is headquartered in Beijing, the People's Republic of China.

NASDAQ ended the session with Niu Technologies rising 8.58% to $4.05 on Wednesday while NASDAQ rose 0.07% to $11,868.80.

Earnings Per Share

As for profitability, Niu Technologies has a trailing twelve months EPS of $0.331.

PE Ratio

Niu Technologies has a trailing twelve months price to earnings ratio of 12.24. Meaning, the purchaser of the share is investing $12.24 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 2.77%.

More news about Niu Technologies.

9. DermTech (DMTK) – 8.54%

DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.

NASDAQ ended the session with DermTech rising 8.54% to $3.56 on Wednesday while NASDAQ jumped 0.07% to $11,868.80.

Earnings Per Share

As for profitability, DermTech has a trailing twelve months EPS of $-3.74.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -64.46%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

DermTech’s EBITDA is 2.48.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is 7.9% and 8.1%, respectively.

More news about DermTech.

10. Castor Maritime (CTRM) – 7.61%

Castor Maritime Inc., through its subsidiaries, engages in ocean transportation of dry bulk cargoes worldwide. It provides seaborne transportation services for dry bulk cargo, including iron ore, coal, grains, steel products, fertilizers, cement, bauxite, sugar, and scrap metals. The company operates three Panamax vessels with a carrying capacity of approximately 76,122 deadweight ton. Castor Maritime Inc. was founded in 2016 and is based in Limassol, Cyprus.

NASDAQ ended the session with Castor Maritime rising 7.61% to $0.71 on Wednesday, following the last session’s upward trend. NASDAQ jumped 0.07% to $11,868.80, after two sequential sessions in a row of gains, on what was a somewhat up trend trading session today.

Earnings Per Share

As for profitability, Castor Maritime has a trailing twelve months EPS of $-0.026.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 30.18%.

Volume

Today’s last reported volume for Castor Maritime is 739145 which is 48.94% below its average volume of 1447710.

More news about Castor Maritime.

Losers Today

1. Diversified Healthcare Trust (DHC) – -7.64%

DHC is a real estate investment trust, or REIT, that owns medical office and life science properties, senior living communities and wellness centers throughout the United States. DHC is managed by the operating subsidiary of The RMR Group Inc., an alternative asset management company that is headquartered in Newton, MA.

NASDAQ ended the session with Diversified Healthcare Trust falling 7.64% to $1.45 on Wednesday while NASDAQ rose 0.07% to $11,868.80.

Earnings Per Share

As for profitability, Diversified Healthcare Trust has a trailing twelve months EPS of $-0.06.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -0.6%.

Yearly Top and Bottom Value

Diversified Healthcare Trust ‘s stock is valued at $1.45 at 17:32 EST, way under its 52-week high of $3.28 and way above its 52-week low of $0.61.

More news about Diversified Healthcare Trust .

2. Corbus Pharmaceuticals Holdings (CRBP) – -7.53%

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. Its lead product candidate is lenabasum, a cannabinoid receptor type 2 (CB2) that is in Phase III clinical trial for the treatment of dermatomyositis; and in Phase II clinical trial to treat systemic lupus erythematosus. The company is also developing cannabinoid receptor type 1 inverse agonist program for treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; and CB2 agonist program for the treatment of cancer. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

NASDAQ ended the session with Corbus Pharmaceuticals Holdings sliding 7.53% to $6.39 on Wednesday, following the last session’s downward trend. NASDAQ rose 0.07% to $11,868.80, after two sequential sessions in a row of gains, on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, Corbus Pharmaceuticals Holdings has a trailing twelve months EPS of $-29.72.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -82.95%.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter is a negative 70.4% and positive 28.8% for the next.

Moving Average

Corbus Pharmaceuticals Holdings’s worth is way higher than its 50-day moving average of $3.90 and way above its 200-day moving average of $5.33.

More news about Corbus Pharmaceuticals Holdings.

3. Entera Bio Ltd. (ENTXW) – -7.14%

NASDAQ ended the session with Entera Bio Ltd. sliding 7.14% to $0.06 on Wednesday while NASDAQ rose 0.07% to $11,868.80.

Yearly Top and Bottom Value

Entera Bio Ltd.’s stock is valued at $0.06 at 17:32 EST, higher than its 52-week high of $0.06.

More news about Entera Bio Ltd..

4. 89bio (ETNB) – -7.06%

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop BIO89-100 for the treatment of severe hypertriglyceridemia. 89bio, Inc. was founded in 2018 and is based in San Francisco, California.

NASDAQ ended the session with 89bio falling 7.06% to $10.93 on Wednesday, after five consecutive sessions in a row of losses. NASDAQ rose 0.07% to $11,868.80, after two sequential sessions in a row of gains, on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, 89bio has a trailing twelve months EPS of $-3.82.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -69.29%.

Volume

Today’s last reported volume for 89bio is 1633910 which is 46.61% above its average volume of 1114440.

Moving Average

89bio’s value is way under its 50-day moving average of $12.70 and way above its 200-day moving average of $7.98.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 46.9% and 51.6%, respectively.

More news about 89bio.

5. Zai Lab (ZLAB) – -6.58%

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.

NASDAQ ended the session with Zai Lab sliding 6.58% to $30.36 on Wednesday, following the last session’s upward trend. NASDAQ jumped 0.07% to $11,868.80, after two consecutive sessions in a row of gains, on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, Zai Lab has a trailing twelve months EPS of $-4.05.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -44.05%.

Volatility

Zai Lab’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.35%, a negative 1.29%, and a positive 4.62%.

Zai Lab’s highest amplitude of average volatility was 6.99% (last week), 5.44% (last month), and 4.62% (last quarter).

Sales Growth

Zai Lab’s sales growth is 27.6% for the ongoing quarter and 40.9% for the next.

More news about Zai Lab.

6. Enochian Biosciences (ENOB) – -6.14%

Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.

NASDAQ ended the session with Enochian Biosciences falling 6.14% to $1.07 on Wednesday, following the last session’s downward trend. NASDAQ jumped 0.07% to $11,868.80, after two consecutive sessions in a row of gains, on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, Enochian Biosciences has a trailing twelve months EPS of $-2.15.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -93.41%.

Yearly Top and Bottom Value

Enochian Biosciences’s stock is valued at $1.07 at 17:32 EST, way below its 52-week high of $8.88 and way above its 52-week low of $0.90.

Moving Average

Enochian Biosciences’s worth is under its 50-day moving average of $1.11 and way under its 200-day moving average of $1.86.

More news about Enochian Biosciences.

7. FIRST REPUBLIC BANK (FRC) – -5.14%

First Republic Bank, together with its subsidiaries, provides private banking, private business banking, and private wealth management services to clients in metropolitan areas in the United States. It operates in two segments, Commercial Banking and Wealth Management. The company accepts deposit products, such as noninterest-bearing checking, interest-bearing checking, money market checking accounts, money market savings accounts, and passbook accounts, as well as certificates of deposit. It also offers a range of lending products that comprise residential mortgage loans, home equity lines of credit, multifamily loans, commercial real estate and construction loans, personal and business loans, single family construction loans, and other loans and lines of credit to businesses and individuals. The company's loans are secured by single family residences, multifamily buildings, and commercial real estate properties. In addition, it provides wealth management services, which include various investment strategies and products, online investment management, trust and custody, full service and online brokerage, financial and estate planning, and access to alternative investments, as well as investing, insurance, and foreign exchange services. Further, the company offers online and mobile banking services; refinancing services; and ATM and debit cards. As of December 31, 2021, it offered its services through 82 licensed deposit taking offices primarily in the San Francisco, Palo Alto, Los Angeles, Santa Barbara, Newport Beach and San Diego, California; Portland, Oregon; Boston, Massachusetts; Palm Beach, Florida; Greenwich, Connecticut; New York, New York; and Jackson, Wyoming. It also has 12 additional offices that offer lending, wealth management, or trust services. First Republic Bank was founded in 1985 and is headquartered in San Francisco, California.

NYSE ended the session with FIRST REPUBLIC BANK sliding 5.14% to $14.96 on Wednesday, after two sequential sessions in a row of gains. NYSE fell 0.35% to $14,933.06, after two successive sessions in a row of gains, on what was a somewhat negative trend exchanging session today.

Earnings Per Share

As for profitability, FIRST REPUBLIC BANK has a trailing twelve months EPS of $6.4.

PE Ratio

FIRST REPUBLIC BANK has a trailing twelve months price to earnings ratio of 2.34. Meaning, the purchaser of the share is investing $2.34 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.99%.

More news about FIRST REPUBLIC BANK.

8. Funko (FNKO) – -4.97%

Funko, Inc., a pop culture consumer products company, designs, sources, and distributes licensed pop culture products in the United States, Europe, and internationally. The company offers vinyl, blind-packed miniature, and action figures; plush products; accessories; apparels, such as t-shirts and hats; homewares, including drinkware, party lights and other home accessories, such as keychains, pens, and pins; and bags, purses and wallets, and board games. It offers its products under the Pop!, Loungefly, Mystery Minis, Paka Paka, Funko Soda, and Snapsies brand names; and licenses its properties under the classic evergreen, movie release, current TV, and current video game categories. The company sells its products to specialty retailers, mass-market retailers, e-commerce sites, and distributors; and at specialty licensing and comic book shows, conventions, and exhibitions, as well as through its e-commerce business. Funko, Inc. was incorporated in 2017 and is headquartered in Everett, Washington.

NASDAQ ended the session with Funko sliding 4.97% to $7.84 on Wednesday, following the last session’s upward trend. NASDAQ jumped 0.07% to $11,868.80, after two consecutive sessions in a row of gains, on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, Funko has a trailing twelve months EPS of $-0.18.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -1.33%.

Yearly Top and Bottom Value

Funko’s stock is valued at $7.84 at 17:32 EST, way under its 52-week high of $27.79 and higher than its 52-week low of $7.14.

More news about Funko.

9. Gevo (GEVO) – -4.86%

Gevo, Inc. operates as a renewable fuels company. It operates through four segments: Gevo, Agri-Energy, Renewable Natural Gas, and Net-Zero. The company commercializes gasoline, jet fuel, and diesel fuel to achieve zero carbon emissions, and reduce greenhouse gas emissions with sustainable alternatives. Its products also include renewable gasoline and diesel, isooctane, isobutanol, sustainable aviation fuel, renewable natural gas, isobutylene, ethanol, and animal feed and protein. Gevo, Inc. has a strategic alliance with Axens North America, Inc. for ethanol-to-jet technology and sustainable aviation fuel commercial project development. The company was formerly known as Methanotech, Inc. and changed its name to Gevo, Inc. in March 2006. Gevo, Inc. was incorporated in 2005 and is headquartered in Englewood, Colorado.

NASDAQ ended the session with Gevo dropping 4.86% to $1.67 on Wednesday while NASDAQ rose 0.07% to $11,868.80.

Earnings Per Share

As for profitability, Gevo has a trailing twelve months EPS of $-0.706.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -15.05%.

More news about Gevo.

10. FuboTV (FUBO) – -4.76%

fuboTV Inc. operates a live TV streaming platform for live sports, news, and entertainment content in the United States and internationally. Its fuboTV platform allows customers to access content through streaming devices, as well as on SmartTVs, computers, mobile phones, and tablets. The company is headquartered in New York, New York.

NYSE ended the session with FuboTV dropping 4.76% to $1.20 on Wednesday while NYSE dropped 0.35% to $14,933.06.

Earnings Per Share

As for profitability, FuboTV has a trailing twelve months EPS of $-3.735.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -99.5%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 43.5%, now sitting on 919.78M for the twelve trailing months.

More news about FuboTV.

Stay up to date with our winners and losers daily report